- Admin
- #1
Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Engineered T Cells Market Research Report by Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Engineered T Cells Market is expected to grow from USD 1,385.02 Million in 2020 to USD 4,174.97 Million by the end of 2025.Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Engineered T Cells Market including Autolus, Bellicum Pharmaceuticals, Inc., Cell Medica, Elli Lilly and Company, Gilead, Juno Therapeutics, Inc., Novartis AG, Oxford BioMedica, Pfizer Inc., and Precision Biosciences.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Engineered T Cells Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report answers questions such as:1. What is the market size and forecast of the Global Engineered T Cells Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Engineered T Cells Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Engineered T Cells Market?4. What is the competitive strategic window for opportunities in the Global Engineered T Cells Market?5. What are the technology trends and regulatory frameworks in the Global Engineered T Cells Market?6. What are the modes and strategic moves considered suitable for entering the Global Engineered T Cells Market?Key Topics Covered: 1. Preface1.1. Objectives of the Study1.2. Market Segmentation & Coverage1.3. Years Considered for the Study1.4. Currency & Pricing1.5. Language1.6. Limitations1.7. Stakeholders2. Research Methodology2.1. Research Process2.2. Research Execution2.3. Research Outcome3. Executive Summary3.1. Introduction3.2. Market Outlook3.3. Application Outlook3.4. Type Outlook3.5. End User Outlook3.6. Geography Outlook3.7. Competitor Outlook4. Market Overview4.1. Introduction4.2. Cumulative Impact of COVID-195. Market Insights5.1. Market Dynamics5.1.1. Drivers5.1.2. Restraints5.1.3. Opportunities5.1.4. Challenges5.2. Porters Five Forces Analysis5.2.1. Threat of New Entrants5.2.2. Threat of Substitutes5.2.3. Bargaining Power of Customers5.2.4. Bargaining Power of Suppliers5.2.5. Industry Rivalry6. Global Engineered T Cells Market, By Type6.1. Introduction6.2. Chimeric Antigen Receptor (CAR)6.3. T Cell Receptor (TCR)6.4. Tumor-Infiltrating Lymphocytes7. Global Engineered T Cells Market, By Application7.1. Introduction7.2. Breast Cancer7.3. Colorectal Cancer7.4. Leukemia7.5. Lung Cancer7.6. Melanoma8. Global Engineered T Cells Market, By End User8.1. Introduction8.2. Cancer Research Centers8.3. Clinics8.4. Hospitals9. Americas Engineered T Cells Market9.1. Introduction9.2. Argentina9.3. Brazil9.4. Canada9.5. Mexico9.6. United States10. Asia-Pacific Engineered T Cells Market11. Europe, Middle East & Africa Engineered T Cells Market12. Competitive Landscape12.1. FPNV Positioning Matrix12.2. Market Ranking Analysis12.3. Market Share Analysis12.4. Competitor SWOT Analysis12.5. Competitive Scenario13. Company Usability Profiles13.1. Autolus13.2. Bellicum Pharmaceuticals, Inc.13.3. Cell Medica13.4. Elli Lilly and Company13.5. Gilead13.6. Juno Therapeutics, Inc.13.7. Novartis AG13.8. Oxford BioMedica13.9. Pfizer Inc.13.10. Precision BiosciencesFor more information about this report visit https://www.researchandmarkets.com/r/dgd1wx CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900